Last reviewed · How we verify
Comparator: Diclofenac sodium
Diclofenac sodium inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
Diclofenac sodium inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever. Used for Acute pain and inflammation, Rheumatoid arthritis, Osteoarthritis.
At a glance
| Generic name | Comparator: Diclofenac sodium |
|---|---|
| Sponsor | Organon and Co |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | COX-1, COX-2 |
| Modality | Small molecule |
| Therapeutic area | Pain Management, Rheumatology, Inflammation |
| Phase | Phase 3 |
Mechanism of action
Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively blocks COX-1 and COX-2 enzymes. By inhibiting prostaglandin production, it reduces inflammatory mediators and provides analgesic and antipyretic effects. It is commonly used for short-term pain relief and inflammation management in various acute and chronic conditions.
Approved indications
- Acute pain and inflammation
- Rheumatoid arthritis
- Osteoarthritis
- Ankylosing spondylitis
- Postoperative pain
Common side effects
- Gastrointestinal upset (dyspepsia, nausea)
- Abdominal pain
- Headache
- Dizziness
- Rash
- Increased liver enzymes
Key clinical trials
- Counterpain PXM Versus Diclofenac Versus Piroxicam (PHASE3)
- Continue ESPB & Continue ESPB Combined With SAPB for Thoracotomy (NA)
- Peritoneal Lavage Using Saline or Saline With Ondansetron for Pain Control After Laparoscopic Cholecystectomy (PHASE4)
- Impact of Gel Aromatherapy on Pain for Patients With De Quervain Disease (PHASE4)
- Topical Diclofenac for Prevention of Radiation-induced Dermatitis (NA)
- A Study to Assess Etoricoxib Versus Diclofenac in Chinese Patients With Osteoarthritis of the Knee or Hip (0663-080)(COMPLETED) (PHASE4)
- Investigational Drug Versus an Approved Drug in Patients With Osteoarthritis (0663-061)(COMPLETED) (PHASE3)
- Etoricoxib vs. Diclofenac in OA (0663-805)(COMPLETED) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Comparator: Diclofenac sodium CI brief — competitive landscape report
- Comparator: Diclofenac sodium updates RSS · CI watch RSS
- Organon and Co portfolio CI